GlassScriptPhysician profile
Janice Marie Teer
NPI 1477530434
$8,412.45
in general payments reported to CMS, 2019-2025
51 companies · $1,372 in 2025
The $1,372 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,282 · 2020: $723 · 2021: $1,043 · 2022: $1,152 · 2023: $1,602 · 2024: $1,240 · 2025: $1,372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,212.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,141.87 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $967.68 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $725.42 | 2019-2025 | |
| Lilly USA, LLC | $571.92 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $543.38 | 2022-2025 | |
| Amarin Pharma, INC. | $500.40 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $409.89 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $360.19 | 2022-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $254.16 | 2019-2025 | Xifaxan, Trulance |
| Abbott Laboratories | $226.46 | 2023-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $205.40 | 2019-2024 | Capvaxive, Gardasil 9, Gardasil |
| Allergan, INC. | $176.39 | 2019-2020 | |
| Esperion Therapeutics, INC. | $172.19 | 2020-2024 | Nexletol |
| Astellas Pharma US INC | $167.26 | 2019-2024 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $165.16 | 2019-2025 | Arexvy, Shingrix |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janice Teer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.